BIIB

Biogen
D

BIIB

Arincen57/100B

Biogen operating income 1985–2026

Biogen's operating income in Q3 FY2026, the three months to 30 September 2026, was 128.40M USD, down 79.1% on the same quarter a year before. Biogen's operating income over the last twelve months was 786.90M USD, down 67.8% on the twelve months before. In fiscal year 2025 it was 1.88B USD, down 24.6% on the year before.

Last updated 9 Nov 2026 · Next report 5 Feb 2027

Operating income

Operating income · -9.1% a year over 10 yearsOperating margin

Growth

Fiscal yearPeriod endingOperating incomeGrowthOperating marginGross profitGross marginEBITDA
TTM30 Sept 2026786.90M-67.80%7.64%7.21B70.05%1.45B
FY202531 Dec 20251.88B-24.61%18.98%6.91B69.90%2.95B
FY202431 Dec 20242.49B+18.74%25.74%7.37B76.12%3.00B
FY202331 Dec 20232.10B-27.41%21.32%7.30B74.24%2.38B
FY202231 Dec 20222.89B+3.50%28.40%7.90B77.61%3.54B
FY202131 Dec 20212.79B-39.22%25.42%8.87B80.79%3.92B
FY202031 Dec 20204.59B-34.78%34.16%11.64B86.57%5.11B
FY201931 Dec 20197.04B+19.60%48.98%12.42B86.40%7.74B
FY201831 Dec 20185.89B+10.15%43.77%11.64B86.50%7.01B
FY201731 Dec 20175.35B+3.77%43.55%10.64B86.72%6.61B
FY201631 Dec 20165.15B+5.33%45.00%10.02B87.48%6.39B
FY201531 Dec 20154.89B+23.12%45.44%9.52B88.48%5.62B
FY201431 Dec 20143.97B+57.92%40.94%8.53B87.93%4.60B
FY201331 Dec 20132.52B+36.82%36.29%6.07B87.63%3.02B
FY201231 Dec 20121.84B+6.60%33.34%4.97B90.11%2.20B
FY201131 Dec 20111.72B+38.10%34.16%4.58B90.75%2.10B
FY201031 Dec 20101.25B-3.59%26.48%4.32B91.51%1.62B
FY200931 Dec 20091.30B+6.74%29.59%4.00B91.27%1.80B
FY200831 Dec 20081.21B+55.64%29.62%3.70B90.19%1.67B
FY200731 Dec 2007779.77M+77.21%24.59%2.84B89.43%1.33B
FY200631 Dec 2006440.02M+86.42%16.40%2.41B89.77%868.93M
FY200531 Dec 2005236.04M+443.67%13.77%1.34B78.20%668.05M
FY200431 Dec 200443.42M—2.72%1.04B65.26%522.43M
FY200331 Dec 2003-869.67M-506.62%-467.23%-98.61M-52.98%-804.13M
FY200231 Dec 2002213.88M-40.62%52.91%402.77M99.64%257.75M
FY200131 Dec 2001360.20M+9.70%34.56%905.80M86.90%430.47M
FY200031 Dec 2000328.36M+3.83%35.47%800.47M86.47%530.45M
FY199931 Dec 1999316.25M+65.89%39.81%683.43M86.03%347.35M
FY199831 Dec 1998190.64M+27.97%34.19%483.08M86.64%215.23M
FY199731 Dec 1997148.97M+264.86%34.32%383.86M88.44%168.26M
FY199631 Dec 199640.83M+448.41%14.73%248.57M89.71%56.09M
FY199531 Dec 19957.45M—4.91%141.19M93.08%18.36M
FY199431 Dec 1994-1.91M-108.79%-1.22%146.40M93.64%6.15M
FY199331 Dec 199321.70M-24.13%15.91%130.90M95.97%28.40M
FY199231 Dec 199228.60M—23.12%121.50M98.22%35.70M
FY199131 Dec 1991-1.30M-262.50%-2.12%18.10M29.48%3.80M
FY199031 Dec 1990800.00K—1.60%14.70M29.34%4.60M
FY198931 Dec 1989-9.00M—-31.58%3.30M11.58%-5.70M
FY198831 Dec 1988-11.90M—-57.77%-500.00K-2.43%-8.80M
FY198731 Dec 1987-24.20M—-281.40%-12.40M-144.19%-20.40M
FY198631 Dec 1986-29.10M—-454.69%-16.90M-264.06%-25.00M
FY198531 Dec 1985-32.90M—-217.88%10.60M70.20%-28.40M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,EPS,Shares outstanding,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Biogen's operating income

Source: Financial Modeling Prep